50 ml of semaglutide Ozempic (Semaglutide Injection) 0.25mg or 0.5mg — Mountainside Medical India to See 50+ Semaglutide

GLP-1 signals to the brain and body that it is time to break down the food someone has eaten and turn it into usable energy

The effects of delayed gastric emptying may further compound the risk factors harbored by the obese, diabetic patient: Gastroparesis secondary to diabetes-related autonomic dysfunction Bowel dysmotility from opioids (chronic pain) and prolonged bed-rest Altered oesophageal-gastric anatomy from bariatric surgery Gastric insufflation from overzealous bag-valve ventilation with high PEEP and difficult airway Reduced efficacy of routine antiemetic regime Nausea and vomiting are reported by approximately 50% of patients using GLP-1 agonists, as direct results of reduced gastric motility and activation of central satiety centers

The most commonly reported side effects included gastrointestinal issues consistent with other GLP-1s, such as nausea, vomiting, and diarrhea

Commonly, lip eczema is from a reaction, such as an allergic reaction, to some type of external substance

The practical rule: use a U-100 syringe for semaglutide, tirzepatide, and similar compounded peptides reconstituted at 1 mg/ml

3 year in a Gastroenterology Hepatology training program